JP2005527547A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527547A5 JP2005527547A5 JP2003579739A JP2003579739A JP2005527547A5 JP 2005527547 A5 JP2005527547 A5 JP 2005527547A5 JP 2003579739 A JP2003579739 A JP 2003579739A JP 2003579739 A JP2003579739 A JP 2003579739A JP 2005527547 A5 JP2005527547 A5 JP 2005527547A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- trefoil peptide
- agent
- chemotherapeutic agent
- trefoil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000007641 Trefoil Factors Human genes 0.000 claims 13
- 108010007389 Trefoil Factors Proteins 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 239000002246 antineoplastic agent Substances 0.000 claims 10
- 102100005582 TFF3 Human genes 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 4
- 229960003685 Imatinib mesylate Drugs 0.000 claims 2
- 102000014456 Trefoil Factor-3 Human genes 0.000 claims 2
- 108010078184 Trefoil Factor-3 Proteins 0.000 claims 2
- 230000002921 anti-spasmodic Effects 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- 229960004117 Capecitabine Drugs 0.000 claims 1
- 206010009887 Colitis Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 229960004397 Cyclophosphamide Drugs 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- 229960002949 Fluorouracil Drugs 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 208000001297 Phlebitis Diseases 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 230000000202 analgesic Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 201000010927 mucositis Diseases 0.000 claims 1
- 231100000017 mucous membrane irritation Toxicity 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
Claims (25)
- (i)トレフォイル・ペプチドと(ii)治療剤とを含む薬学的組成物。
- トレフォイル・ペプチドが、鎮痙性ポリペプチド、pS2、腸トレフォイル・ファクター、又は生物学的活性を有するそれらの断片である、請求項1記載の組成物。
- トレフォイル・ペプチドが、ITF1-73、ITF15-73、又はITF21-73である、請求項1記載の組成物。
- トレフォイル・ペプチドが、配列番号:7〜10と実質的に同一の配列を有するポリペプチドを含む、請求項1記載の組成物。
- 治療剤が化学療法剤である、請求項1〜4のいずれか一項記載の組成物。
- 化学療法剤が、ブスルファン、テモゾロマイド、エトポシド、メルファラン、5-フルオロウラシル、カペシタビン、シクロホスファミド、メトトレキサート、及びメシル酸イマチニブからなる群より選択される、請求項5記載の組成物。
- 化学療法剤がメシル酸イマチニブである、請求項6記載の組成物。
- 経口投与又は静脈内投与に適したものである、請求項1〜7のいずれか一項記載の組成物。
- 治療剤が抗炎症剤である、請求項1〜4のいずれか一項記載の組成物。
- 治療剤が、抗菌剤、抗ウイルス剤、又は抗真菌剤である、請求項1〜4のいずれか一項記載の組成物。
- 治療剤が鎮痛剤である、請求項1〜4のいずれか一項記載の組成物。
- 化学療法剤が投与される患者における有害効果を減少させる方法であって、該化学療法剤投与の14日以内に、該有害効果を減少させるのに十分な量のトレフォイル・ペプチドを該患者に投与することを含む方法。
- トレフォイル・ペプチドが、鎮痙性ポリペプチド、pS2、腸トレフォイル・ファクター、又は生物学的活性を有するそれらの断片である、請求項12記載の方法。
- トレフォイル・ペプチドが、ITF1-73、ITF15-73、又はITF21-73である、請求項12記載の方法。
- トレフォイル・ペプチドが、配列番号7〜10と実質的に同一の配列を有するポリペプチドを含む、請求項12記載の方法。
- トレフォイル・ペプチド及び化学療法剤が同時に投与される、請求項12〜15のいずれか一項記載の方法。
- トレフォイル・ペプチド及び化学療法剤が、一つの薬学的に許容される組成物の中に存在する、請求項12〜16のいずれか一項記載の方法。
- 組成物が、経口投与又は静脈内投与に適したものである、請求項12〜17のいずれか一項記載の方法。
- 有害効果が粘膜炎である、請求項12〜18のいずれか一項記載の方法。
- 有害効果が腸炎又は結腸炎である、請求項12〜18のいずれか一項記載の方法。
- 有害効果が粘膜刺激である、請求項12〜18のいずれか一項記載の方法。
- 有害効果が静脈炎である、請求項12〜18のいずれか一項記載の方法。
- トレフォイル・ペプチド及び化学療法剤が、異なる薬学的に許容される組成物に含まれ投与される、請求項12〜16のいずれか一項記載の方法。
- トレフォイル・ペプチドが化学療法剤の前に投与される、請求項23記載の方法。
- トレフォイル・ペプチドが化学療法剤の後に投与される、請求項23記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36757402P | 2002-03-26 | 2002-03-26 | |
US42270802P | 2002-10-31 | 2002-10-31 | |
PCT/US2003/009195 WO2003082196A2 (en) | 2002-03-26 | 2003-03-26 | Combination therapy using trefoil peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005527547A JP2005527547A (ja) | 2005-09-15 |
JP2005527547A5 true JP2005527547A5 (ja) | 2006-03-23 |
Family
ID=28678188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003579739A Pending JP2005527547A (ja) | 2002-03-26 | 2003-03-26 | トレフォイル・ペプチドを使用した組み合わせ療法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20030186880A1 (ja) |
EP (1) | EP1494530A4 (ja) |
JP (1) | JP2005527547A (ja) |
CN (1) | CN1655675A (ja) |
AU (1) | AU2003224773B2 (ja) |
CA (1) | CA2480372A1 (ja) |
MX (1) | MXPA04009363A (ja) |
WO (1) | WO2003082196A2 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6525018B1 (en) | 1999-05-17 | 2003-02-25 | The General Hospital Corp. | Treating eye disorders using intestinal trefoil proteins |
US20030185838A1 (en) * | 2001-11-28 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating lesions of the respiratory epithelium |
US20030186882A1 (en) * | 2001-07-31 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating and preventing distal bowel lesions |
US7538082B2 (en) | 2001-04-24 | 2009-05-26 | The General Hospital Corporation | Methods and compositions for treating oral and esophageal lesions |
US20040171544A1 (en) * | 2001-04-24 | 2004-09-02 | Barker Nicholas P. | Trefoil domain-containing polypeptides and uses thereof |
US20060189526A1 (en) * | 2002-04-24 | 2006-08-24 | Podolsky Daniel K | Compositions containing an intestinal trefoil peptide and a mucoadhesive |
US20030105016A1 (en) * | 2001-09-06 | 2003-06-05 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
US20030181384A1 (en) * | 2001-09-06 | 2003-09-25 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
US20030185839A1 (en) * | 2001-10-05 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating dermal lesions |
EP1438062A4 (en) * | 2001-10-05 | 2005-06-01 | Gen Hospital Corp | METHOD AND COMPOSITIONS FOR TREATING SKIN Lions |
US20060188471A1 (en) * | 2002-10-31 | 2006-08-24 | Podolsky Daniel K | Methods of treating epithelial lesions |
EP1581623A2 (en) * | 2002-10-31 | 2005-10-05 | The GI Company, Inc | Trefoil domain-containing polypeptides and uses thereof |
US8075771B2 (en) * | 2005-02-17 | 2011-12-13 | E. I. Du Pont De Nemours And Company | Apparatus for magnetic field gradient enhanced centrifugation |
CN100381560C (zh) * | 2005-09-27 | 2008-04-16 | 中国人民解放军第三军医大学第一附属医院 | 采用gs115酵母菌合成重组人肠三叶因子的工艺 |
WO2013176785A1 (en) * | 2012-05-21 | 2013-11-28 | The Trustees Of Columbia University In The City Of New York | Trefoil family factor and uses thereof |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
US11090358B2 (en) | 2015-09-09 | 2021-08-17 | Fred Hutchinson Cancer Research Center | Cartilage-homing peptides |
AU2017322523A1 (en) * | 2016-09-09 | 2019-02-21 | Blaze Bioscience, Inc. | Stable peptides and methods of use thereof |
CA3049262A1 (en) | 2017-01-18 | 2018-07-26 | Fred Hutchinson Cancer Research Center | Peptide compositions and methods of use thereof for disrupting tead interactions |
JP7280193B2 (ja) | 2017-03-16 | 2023-05-23 | ブレイズ バイオサイエンス, インコーポレイテッド | 軟骨ホーミングペプチドコンジュゲート及びその使用方法 |
WO2018232122A1 (en) | 2017-06-15 | 2018-12-20 | Blaze Bioscience, Inc. | Renal-homing peptide conjugates and methods of use thereof |
US11866466B2 (en) | 2017-12-19 | 2024-01-09 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
US20230173028A1 (en) * | 2020-03-30 | 2023-06-08 | Shandong Ruiying Pioneer Pharmaceutical Co., Ltd | Application of TFF2 Protein and IFN-k Protein Combination in Treatment of a Novel Coronavirus Infection |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US151472A (en) * | 1874-06-02 | Improvement in rotary engines | ||
US4370317A (en) * | 1980-09-10 | 1983-01-25 | Novo Industri A/S | Pancreatic spasmolytic polypeptide |
US5843701A (en) * | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
US6221840B1 (en) * | 1991-02-14 | 2001-04-24 | The General Hospital Corporation | Intestinal trefoil proteins |
US6063755A (en) * | 1991-02-14 | 2000-05-16 | The General Hospital Corporation | Intestinal trefoil proteins |
US5703047A (en) * | 1992-09-21 | 1997-12-30 | Board Of Regents, The University Of Texas System | Methods and treatments for corneal healing with growth factors |
DK6893D0 (da) * | 1993-01-21 | 1993-01-21 | Novo Nordisk As | Peptid |
US5563046A (en) * | 1993-08-02 | 1996-10-08 | Celtrix Pharmaceuticals, Inc. | Fusion polypeptides and proteins |
US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
CZ289705B6 (cs) * | 1994-08-26 | 2002-03-13 | Novo Nordisk A/S | Trojlístkový peptid, způsob přípravy, farmaceutický prostředek a pouľití trojlístkového peptidu |
US6525018B1 (en) * | 1999-05-17 | 2003-02-25 | The General Hospital Corp. | Treating eye disorders using intestinal trefoil proteins |
US20030185838A1 (en) * | 2001-11-28 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating lesions of the respiratory epithelium |
US20030186882A1 (en) * | 2001-07-31 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating and preventing distal bowel lesions |
WO1999010377A1 (en) * | 1997-08-25 | 1999-03-04 | The General Hospital Corporation | Receptor for intestinal trefoil factor |
JP2002523452A (ja) * | 1998-08-26 | 2002-07-30 | スミスクライン・ビーチャム・コーポレイション | 肺疾患の治療方法 |
US6372439B2 (en) * | 1998-10-01 | 2002-04-16 | James R. Goldenring | Screen for gastric adenocarcinoma |
ATE480623T1 (de) * | 1999-07-05 | 2010-09-15 | Actogenix Nv | Bereitstellung von peptiden mit kleeblattstruktur |
US20030040478A1 (en) * | 1999-12-08 | 2003-02-27 | Drucker Daniel J | Chemotherapy treatment |
WO2001046475A1 (en) * | 1999-12-23 | 2001-06-28 | Human Genome Sciences, Inc. | Trefoil domain-containing polynucleotides, polypeptides, and antibodies |
WO2002041837A2 (en) * | 2000-11-22 | 2002-05-30 | Rxkinetix, Inc. | Treatment of mucositis |
US7538082B2 (en) * | 2001-04-24 | 2009-05-26 | The General Hospital Corporation | Methods and compositions for treating oral and esophageal lesions |
US20030166535A1 (en) * | 2001-04-24 | 2003-09-04 | Podolsky Daniel K. | Methods and compositions for treating oral and esophageal lesions |
US20030105016A1 (en) * | 2001-09-06 | 2003-06-05 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
US20030153496A1 (en) * | 2001-06-14 | 2003-08-14 | Lars Thim | Mucosal repair by TFF dimer peptides |
EP1418930A2 (en) * | 2001-06-14 | 2004-05-19 | Novo Nordisk A/S | Mucosal repair by tff2 peptides |
WO2003011117A2 (en) * | 2001-07-31 | 2003-02-13 | The General Hospital Corporation | Methods and compositions for treating and preventing distal bowel lesions |
US20030181384A1 (en) * | 2001-09-06 | 2003-09-25 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
EP1438062A4 (en) * | 2001-10-05 | 2005-06-01 | Gen Hospital Corp | METHOD AND COMPOSITIONS FOR TREATING SKIN Lions |
US20030185839A1 (en) * | 2001-10-05 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating dermal lesions |
MXPA04005053A (es) * | 2001-11-28 | 2004-09-10 | Gen Hospital Corp | Metodos y composiciones para tratar lesiones del epitelio respiratorio. |
US20030215431A1 (en) * | 2002-02-11 | 2003-11-20 | Lars Thim | Management of mucosal viscosity by TFF monomer peptides |
US6780383B1 (en) * | 2003-02-28 | 2004-08-24 | Eugene Ettlinger | System for sterilization of spaces and surfaces |
US6984628B2 (en) * | 2003-07-15 | 2006-01-10 | Allergan, Inc. | Ophthalmic compositions comprising trefoil factor family peptides |
BRPI0610352A2 (pt) * | 2005-05-18 | 2010-06-15 | Gi Company Inc | sistema de administração de fármaco oral e métodos de utilização do mesmo |
EP1907562A2 (en) * | 2005-07-25 | 2008-04-09 | The GI Company, Inc | Yeast expression vectors for production of itf |
-
2003
- 2003-03-26 MX MXPA04009363A patent/MXPA04009363A/es unknown
- 2003-03-26 CA CA002480372A patent/CA2480372A1/en not_active Abandoned
- 2003-03-26 WO PCT/US2003/009195 patent/WO2003082196A2/en active Application Filing
- 2003-03-26 AU AU2003224773A patent/AU2003224773B2/en not_active Ceased
- 2003-03-26 EP EP03721462A patent/EP1494530A4/en not_active Withdrawn
- 2003-03-26 CN CNA038120402A patent/CN1655675A/zh active Pending
- 2003-03-26 US US10/397,953 patent/US20030186880A1/en not_active Abandoned
- 2003-03-26 JP JP2003579739A patent/JP2005527547A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005527547A5 (ja) | ||
US6509154B1 (en) | Product comprising at least a double stranded RNA combined with at least an antiviral agent | |
ES2333399T3 (es) | Metodos para tratar una leucemia. | |
JP2009504157A5 (ja) | ||
AU2003224773B2 (en) | Combination therapy using trefoil peptides | |
CA2359812A1 (en) | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures | |
JP2005515966A5 (ja) | ||
RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
JP2015057436A5 (ja) | ||
DK1453487T3 (da) | Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud | |
JP2818299B2 (ja) | ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用 | |
WO1997006804A1 (en) | 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c | |
CA2671470A1 (en) | Powder formulation for valganciclovir | |
JP2008526953A (ja) | 炎症性疾患のプラジカンテルでの治療 | |
JP2013508425A (ja) | Bi201335、インターフェロンアルファおよびリバビリンを含むhcvの併用療法のための投薬処置計画 | |
RU2002105485A (ru) | Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α) | |
JP2005501825A5 (ja) | ||
JP2007501806A5 (ja) | ||
JP2007504223A5 (ja) | ||
CA2141951C (en) | Inhibition of retrovirus infection | |
JP2005500981A5 (ja) | ||
JP2007523215A5 (ja) | ||
JP2012504941A5 (ja) | ||
JP2007504222A5 (ja) | ||
ES2286433T3 (es) | Uso de urdina-5'-monofosfato o de citidina-5'-monofosfato para el tratamiento de lesiones del sistema nervioso periferico. |